Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized open-label study of MORAb-202 in previously treated metastatic NSCLC adenocarcinoma
2022-000131-23Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of farletuzumab ecteribulin in non-small cell lung cancer (NSCLC) and Non-small cell lung cancer adenocarcinoma (NSCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Incidence and severity of adverse events and serious adverse events. Started Sep 2022; status: active.
02
Drugs
farletuzumab ecteribulin
03
Conditions
non-small cell lung cancer (NSCLC)Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on 2022-000131-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000131-23.